Literature DB >> 9076557

Effect of blood gas derangement on QTc dispersion in severe chronic obstructive pulmonary disease: evidence of an electropathy?

B Sarubbi1, V Esposito, V Ducceschi, I Meoli, E Grella, L Santangelo, A Iacano, M Caputi.   

Abstract

Cardiac arrhythmias are common in patients with respiratory failure from chronic obstructive pulmonary disease (COPD). Several factors may be potentially arrhythmogenic in these patients, including hypoxemia and hypercapnia, acid-base disturbances, cor pulmonale and the use of digitalis, methylxanthines, and sympathomimetic drugs. The aim of this study was to examine the effect of hypoxemia and hypercapnia on QTc dispersion (QTcD) in COPD patients, and to evaluate the effect of a partial correction of one of these pro-arrhythmic factors, the hypoxemia, on Qtc dispersion, as QTcD has been proposed as a marker of heterogeneous repolarization and, hence of ventricular electrical instability. We showed that in 15 hypoxemic/hypercapnic COPD patients, compared to 20 controls, the QTcD was significantly higher (49.7 +/- 10.6 vs. 22.9 +/- 9.8 ms; P = 0.0001); furthermore, after only 24 h of oxygen therapy, and hence after a partial correction of hypoxemia, there was a significant reduction in QTcD in COPD patients (49.7 +/- 10.6 vs. 36.3 +/- 10.1 ms; P = 0.018). The data of the present study suggest that the increase in QTcD may be an early marker of a blood gas mediated electropathy in COPD patients.

Entities:  

Mesh:

Year:  1997        PMID: 9076557     DOI: 10.1016/s0167-5273(96)02876-8

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  17 in total

Review 1.  Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease.

Authors:  M Cazzola; C F Donner; M G Matera
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  QT dispersion: time for a revival?

Authors:  Alessandro Celi
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

3.  Lower arrythmogenic risk of low dose albuterol plus ipratropium.

Authors:  H Yuksel; S Coskun; M Polat; A Onag
Journal:  Indian J Pediatr       Date:  2001-10       Impact factor: 1.967

4.  Ventricular repolarization time indexes following anthracycline treatment.

Authors:  B Sarubbi; M Orditura; V Ducceschi; F De Vita; L Santangelo; F Ciaramella; G Catalano; A Iacono
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

5.  Increased QT dispersion: a negative prognostic finding in chronic obstructive pulmonary disease.

Authors:  Roberto Zulli; Paolo Donati; Franco Nicosia; Massimiliano De Vecchi; Claudio Tantucci; Giuseppe Romanelli; Vittorio Grassi
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

6.  Evaluation of atrial conduction features with tissue Doppler imaging in patients with chronic obstructive pulmonary disease.

Authors:  Ilker Murat Caglar; Tolga Dasli; Fatma Nihan Turhan Caglar; Mehmet Kamil Teber; Murat Ugurlucan; Gokhan Ozmen
Journal:  Clin Res Cardiol       Date:  2012-03-06       Impact factor: 5.460

Review 7.  Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease.

Authors:  M Cazzola; C F Donner
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

8.  Chronic obstructive pulmonary disease and the risk of cardiovascular diseases.

Authors:  Cornelia Schneider; Ulrich Bothner; Susan S Jick; Christoph R Meier
Journal:  Eur J Epidemiol       Date:  2010-02-27       Impact factor: 8.082

9.  QT dispersion in patients with chronic heart failure: beta blockers are associated with a reduction in QT dispersion.

Authors:  C E Bonnar; A P Davie; L Caruana; L Fenn; S A Ogston; J J McMurray; A D Struthers
Journal:  Heart       Date:  1999-03       Impact factor: 5.994

10.  Factors associated with the development of atrial fibrillation in COPD patients: the role of P-wave dispersion.

Authors:  Tufan Tükek; Pinar Yildiz; Vakur Akkaya; Mehmet Akif Karan; Dursun Atilgan; Veysel Yilmaz; Ferruh Korkut
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-07       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.